Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jardiance is a prescription sodium-glucose cotransporter 2 inhibitor containing empagliflozin. Current labeling includes glycemic control in adults and children age 10 and older with type 2 diabetes, cardiovascular risk reduction in selected adults with type 2 diabetes, heart failure treatment in adults, and chronic kidney disease treatment in adults at risk of progression.
read more about jardiance ...Empagliflozin inhibits sodium-glucose cotransporter 2 in the kidneys. This reduces reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion.
Jardiance is used for type 2 diabetes glycemic control in adults and pediatric patients age 10 and older. Adult indications also include reduction of cardiovascular death in type 2 diabetes with established cardiovascular disease, reduction of cardiovascular death and hospitalization in heart failure, and reduction of selected kidney and cardiovascular outcomes in chronic kidney disease at risk of progression.
The recommended dose is 10 mg once daily in the morning with or without food. For additional glycemic control, the dose can increase to 25 mg once daily in patients who tolerate 10 mg. The 10 mg dose is used for the labeled heart failure, chronic kidney disease, and cardiovascular risk reduction indications.
Serious concerns include ketoacidosis, volume depletion, serious urinary and genital infections, Fournier gangrene, low blood glucose when combined with insulin or insulin secretagogues, lower limb amputation, and severe hypersensitivity. Current labeling directs withholding Jardiance for at least three days before surgery or procedures associated with prolonged fasting when possible.
Current labeling includes type 2 diabetes, heart failure, and chronic kidney disease under indication-specific criteria.
The recommended starting dose is 10 mg once daily in the morning with or without food.
Yes. For additional glycemic control, the dose can increase to 25 mg once daily in patients who tolerate 10 mg.
Yes. Current labeling includes glycemic control in pediatric patients age 10 and older with type 2 diabetes.
Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure. https://pubmed.ncbi.nlm.nih.gov/32865377/. Date Accessed October 6, 2026.
Empagliflozin and Cardiovascular Outcomes and Mortality in Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/26378978/. Date Accessed October 6, 2026.
Empagliflozin in Patients With Chronic Kidney Disease. https://pubmed.ncbi.nlm.nih.gov/36331190/. Date Accessed October 6, 2026.
Empagliflozin: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a614043.html. Date Accessed October 6, 2026.
JARDIANCE (Empagliflozin) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565. Date Accessed October 6, 2026.